Clinical trials
Lupus Erythematosus, Systemic clinical trials
Below are recruiting lupus erythematosus, systemic clinical trials, each written for real people, not researchers. We’re tracking 260 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07607964RecruitingPhase 1
ABBV-519 Study for Lupus or Rheumatoid Arthritis
This early-stage trial tests a new drug called ABBV-519 given as infusions or injections to treat systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in adults whose disease hasn't responded well to other treatments. Researchers will measure how safe the drug is, how it moves through your body, and whether it helps reduce symptoms.
Anniston, AlabamaAges 18–75 - NCT03473912Recruiting
Rheumatoid disease biobank study for adults
This study asks adults with a rheumatoid condition to join a biobank, which is a safe place to store health information and biological samples for future research. It may help researchers better understand rheumatoid conditions and develop better treatments.
Kfar SabaAges 18–120 - NCT04604990Recruiting
National lupus patient study for adults in Saudi Arabia
This study follows adults with systemic lupus erythematosus (lupus) to better understand the condition over time. If you meet common lupus diagnosis standards, you may be able to join—there’s no limit on when you were diagnosed.
Riyadh, Central ProvinceAges 19 years+ - NCT05443516Recruiting
Blood and urine markers in active lupus kidney disease
This study looks at blood and urine markers that may show how active lupus kidney disease is and how it changes over time. It may help doctors better monitor people with active lupus-related kidney inflammation.
BrusselsAges 18–70 - NCT06166199Recruiting
High-intensity interval training for lupus patients
This study tests whether high-intensity interval training (short bursts of intense exercise) can help people with systemic lupus erythematosus (SLE, an autoimmune disease). It aims to see if this type of exercise is safe and improves symptoms.
Stockholm, HuddingeAges 18 years+ - NCT07855302RecruitingPhase 1
CAR T-cell therapy for young people with lupus
This trial tests a treatment that uses a patient's own immune cells, modified to target and calm the overactive immune system causing lupus. It is for young people whose lupus is active despite trying several standard treatments.
SeoulAges Up to 25 years - NCT07829614RecruitingPhase 1
F182112 study for people with lupus
This study tests a new drug called F182112 for people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body. The drug targets certain immune cells to possibly reduce lupus symptoms.
ShanghaiAges 18–65 - NCT07800871RecruitingPhase 1/Phase 2
FT839 cell therapy for autoimmune diseases
This trial tests a new cell therapy (FT839) designed to target and reset the immune system's B cells to help treat moderate to severe autoimmune diseases that haven't improved with standard treatments. It's an early-phase study, so the main goals are to see if it's safe and if it helps control the disease.
Fullerton, CaliforniaAges 18–70 - NCT07760480RecruitingPhase 4
Intensified treatment for lupus nephritis
This study tests whether adding a drug called voclosporin to the usual treatment for lupus nephritis (a kidney disease caused by lupus) can better reduce kidney inflammation. It also looks at the role of immune cells in this process.
AmsterdamAges 16–70 - NCT07751848RecruitingPhase 3
Study of anifrolumab for Chinese patients with active lupus
This trial tests anifrolumab, an investigational drug that may help reduce lupus activity in people with moderate-to-severe disease. If you have active lupus despite current treatments, this study might offer a new option.
BeijingAges 18–70 - NCT06593041Recruiting
Platelets in lupus and other autoimmune diseases
This study looks at how platelets (small blood cells that help with clotting) might play a role in autoimmune diseases like lupus. By understanding this, researchers hope to find new ways to treat these conditions.
Strasbourg, FranceAges 18–70 - NCT07720310Enrolling by invitation
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new immune cell therapy (CAR-T) for people with lupus that hasn't gotten better with standard treatments. The goal is to see if these modified cells can calm the overactive immune system and improve symptoms.
Lyasny, Minsk OblastAges 18–70 - NCT07719140RecruitingPhase 4
Lower steroid dose study for children with lupus nephritis
This trial tests whether a lower starting dose of steroids can control kidney inflammation in children with lupus nephritis. It aims to reduce side effects while still treating the disease effectively.
Beijing, Beijing MunicipalityAges 6–18 - NCT06350110RecruitingPhase 1/Phase 2
CAR T cells for lupus
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Beijing, Beijing MunicipalityAges 18–90 - NCT07691970RecruitingPhase 3
Continued treatment study for people who benefited from anifrolumab
This study lets people who finished a previous anifrolumab (Saphnelo) trial and saw benefits continue getting the treatment. It aims to see how well the drug works over a longer time.
Phoenix, ArizonaAges 5–80 - NCT07679776Enrolling by invitation
Study on early vision changes in lupus patients
This study looks at whether people with systemic lupus erythematosus (SLE) have early signs of vision problems. Eye tests will be used to check how well you see and if there are any hidden issues in your eyes.
Hefei, AnhuiAges Any age - NCT06428188RecruitingPhase 1/Phase 2
CAR-T cells targeting BCMA/CD19 for autoimmune diseases
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
Beijing, Beijing MunicipalityAges 21–90 - NCT06675422RecruitingPhase 1/Phase 2
JY231 injection for active lupus
This trial tests an investigational drug called JY231 for people with active systemic lupus erythematosus (SLE) that is not well controlled with standard treatments. The goal is to see if JY231 can reduce lupus activity and improve symptoms.
Kunming, YunnanAges 14–75 - NCT07666711Recruiting
Kidney biomarker study for lupus patients
This study aims to find better ways to detect kidney problems in people with lupus by testing blood and urine samples. If you have lupus, you may help researchers improve how kidney disease is diagnosed and monitored.
Oslo, OsloAges 18 years+ - NCT07657793RecruitingPhase 2/Phase 3
Sirolimus for Lupus-Related Low Platelets
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
Beijing, Beijing MunicipalityAges 18–65 - NCT07649265RecruitingPhase 1
Testing a new drug for autoimmune diseases
This study tests a new drug called HBM7020 to see if it is safe and how well it is absorbed by the body. It is for healthy people and people with certain autoimmune diseases like lupus, scleroderma, rheumatoid arthritis, or Sjögren's disease.
Brisbane, QueenslandAges 18–75 - NCT06691152RecruitingPhase 1
CD19 UCAR T cells for severe lupus
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT07630714RecruitingPhase 2
Testing a new lupus medicine given under the skin in children
This study tests anifrolumab, a new injection medicine that may help control systemic lupus erythematosus (SLE) in children and teens. Researchers will measure how the body processes the medicine and whether it helps reduce lupus activity while monitoring for side effects.
ParkvilleAges 5–17 - NCT07629583RecruitingPhase 1
Testing cevostamab for lupus with kidney involvement
This study tests a new drug called cevostamab for people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body's own tissues. Some participants also have lupus nephritis, which means the disease is affecting their kidneys. The drug may help by targeting a specific part of the immune system.
Toulouse, Haute GaronneAges 18–75
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Lupus Erythematosus, Systemic trials by city
Studies with a site in or near these metro areas.
Lupus Erythematosus, Systemic trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for lupus erythematosus, systemic?
- Yes. Clin2 currently lists 260 recruiting lupus erythematosus, systemic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus erythematosus, systemic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus erythematosus, systemic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.